- Home
- AEON vs IMRN Comparison
AEON vs IMRN Comparison
Compare AEON & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- IMRN
- Stock Information
- Founded
- AEON N/A
- IMRN 1994
- Country
- AEON United States
- IMRN Australia
- Employees
- AEON N/A
- IMRN N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- IMRN Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- IMRN Health Care
- Exchange
- AEON Nasdaq
- IMRN Nasdaq
- Market Cap
- AEON 8.0M
- IMRN 9.2M
- IPO Year
- AEON N/A
- IMRN N/A
- Fundamental
- Price
- AEON $0.73
- IMRN $1.83
- Analyst Decision
- AEON Strong Buy
- IMRN Strong Buy
- Analyst Count
- AEON 1
- IMRN 1
- Target Price
- AEON $360.00
- IMRN $5.00
- AVG Volume (30 Days)
- AEON 85.9K
- IMRN 53.8K
- Earning Date
- AEON 08-12-2025
- IMRN 08-29-2025
- Dividend Yield
- AEON N/A
- IMRN N/A
- EPS Growth
- AEON N/A
- IMRN N/A
- EPS
- AEON N/A
- IMRN N/A
- Revenue
- AEON N/A
- IMRN $4,777,422.00
- Revenue This Year
- AEON N/A
- IMRN N/A
- Revenue Next Year
- AEON N/A
- IMRN N/A
- P/E Ratio
- AEON N/A
- IMRN N/A
- Revenue Growth
- AEON N/A
- IMRN 48.63
- 52 Week Low
- AEON $0.38
- IMRN $1.50
- 52 Week High
- AEON $115.57
- IMRN $2.87
- Technical
- Relative Strength Index (RSI)
- AEON 48.08
- IMRN 55.18
- Support Level
- AEON $0.72
- IMRN $1.73
- Resistance Level
- AEON $0.80
- IMRN $1.88
- Average True Range (ATR)
- AEON 0.06
- IMRN 0.12
- MACD
- AEON 0.00
- IMRN 0.01
- Stochastic Oscillator
- AEON 59.94
- IMRN 64.52
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.